JPWO2021159040A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021159040A5 JPWO2021159040A5 JP2022548194A JP2022548194A JPWO2021159040A5 JP WO2021159040 A5 JPWO2021159040 A5 JP WO2021159040A5 JP 2022548194 A JP2022548194 A JP 2022548194A JP 2022548194 A JP2022548194 A JP 2022548194A JP WO2021159040 A5 JPWO2021159040 A5 JP WO2021159040A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- alkenyl
- independently selected
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132619A JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971825P | 2020-02-07 | 2020-02-07 | |
| US62/971,825 | 2020-02-07 | ||
| US202063016175P | 2020-04-27 | 2020-04-27 | |
| US63/016,175 | 2020-04-27 | ||
| US202063044330P | 2020-06-25 | 2020-06-25 | |
| US63/044,330 | 2020-06-25 | ||
| US202063063137P | 2020-08-07 | 2020-08-07 | |
| US63/063,137 | 2020-08-07 | ||
| PCT/US2021/016979 WO2021159040A2 (en) | 2020-02-07 | 2021-02-06 | Sars-cov-2 mrna domain vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132619A Division JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023513544A JP2023513544A (ja) | 2023-03-31 |
| JP2023513544A5 JP2023513544A5 (https=) | 2023-08-24 |
| JPWO2021159040A5 true JPWO2021159040A5 (https=) | 2023-08-24 |
| JP7438604B2 JP7438604B2 (ja) | 2024-02-27 |
Family
ID=74845093
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548194A Active JP7438604B2 (ja) | 2020-02-07 | 2021-02-06 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2023132619A Active JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A Active JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132619A Active JP7443608B2 (ja) | 2020-02-07 | 2023-08-16 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| JP2024023916A Active JP7832243B2 (ja) | 2020-02-07 | 2024-02-20 | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230346914A1 (https=) |
| EP (1) | EP4100052A2 (https=) |
| JP (3) | JP7438604B2 (https=) |
| KR (1) | KR20220140528A (https=) |
| CN (1) | CN115551545A (https=) |
| AU (1) | AU2021215938A1 (https=) |
| BR (1) | BR112022015565A2 (https=) |
| CA (1) | CA3170150A1 (https=) |
| IL (1) | IL295377A (https=) |
| MX (1) | MX2022009707A (https=) |
| WO (1) | WO2021159040A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| JP2023525936A (ja) * | 2020-05-18 | 2023-06-19 | 康希諾（上海）生物科技有限公司 | ｍＲＮＡ又はｍＲＮＡ組成物、その調製方法及び使用 |
| AU2021294342A1 (en) * | 2020-06-26 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions and methods for inducing an immune response against coronavirus |
| WO2022046583A1 (en) * | 2020-08-24 | 2022-03-03 | Phylex Biosciences, Inc. | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| US20230416309A1 (en) * | 2020-10-23 | 2023-12-28 | Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji | Fusion protein and application thereof |
| CN114517205A (zh) * | 2020-11-20 | 2022-05-20 | 北京震旦鼎泰生物科技有限公司 | 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用 |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| EP4277655A1 (en) * | 2021-01-15 | 2023-11-22 | ModernaTX, Inc. | Variant strain-based coronavirus vaccines |
| US11524023B2 (en) * | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4308156A1 (en) * | 2021-03-15 | 2024-01-24 | ModernaTX, Inc. | Therapeutic use of sars-cov-2 mrna domain vaccines |
| WO2022215036A1 (en) | 2021-04-08 | 2022-10-13 | Vaxthera Sas | Coronavirus vaccine comprising a mosaic protein |
| US20240321387A1 (en) | 2021-05-04 | 2024-09-26 | BioNTech SE | Immunogen selection |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4384212A4 (en) * | 2021-08-15 | 2025-06-25 | Dennis R. Burton | Undirected mutated mrna vaccine |
| EP4387592A4 (en) * | 2021-08-17 | 2025-08-06 | Univ Monash | VACCINE COMPOSITIONS |
| AU2022333308A1 (en) * | 2021-08-24 | 2024-03-07 | Victoria Link Limited | Fusion polypeptide |
| WO2023034991A1 (en) * | 2021-09-02 | 2023-03-09 | Kansas State University Research Foundation | Mrna vaccine formulations and methods of using the same |
| CN113527522B (zh) * | 2021-09-13 | 2021-12-21 | 深圳市瑞吉生物科技有限公司 | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 |
| CN116064598B (zh) * | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| WO2023060483A1 (zh) * | 2021-10-13 | 2023-04-20 | 清华大学 | 多肽-rbd免疫偶联物及其用途 |
| CN118302189A (zh) | 2021-10-21 | 2024-07-05 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US20250026793A1 (en) * | 2021-10-21 | 2025-01-23 | The University Of Melbourne | Chimeric betacoronavirus spike polypeptides |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| EP4436984A1 (en) * | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| TW202333780A (zh) | 2021-11-29 | 2023-09-01 | 德商拜恩技術股份公司 | 冠狀病毒疫苗 |
| IL288634A (en) * | 2021-12-02 | 2023-07-01 | Yeda Res & Dev | Improving the translation and protein secretion efficiency of mRNA vaccines |
| WO2023113094A1 (ko) * | 2021-12-16 | 2023-06-22 | 주식회사 씨티씨백 | 면역원성이 증가된 코로나바이러스감염증-19 백신 조성물 |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| CN116376942A (zh) * | 2021-12-31 | 2023-07-04 | 广州国家实验室 | mRNA疫苗 |
| WO2023142283A1 (zh) | 2022-01-27 | 2023-08-03 | 深圳市瑞吉生物科技有限公司 | 一种新型冠状病毒mRNA疫苗及其制备方法与应用 |
| EP4242308A1 (en) | 2022-01-27 | 2023-09-13 | Shenzhen Rhegen Biotechnology Co., Ltd. | Sars-cov-2 mrna vaccine, and preparation method therefor and use thereof |
| WO2023143600A1 (zh) * | 2022-01-30 | 2023-08-03 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| CN116554042A (zh) * | 2022-01-30 | 2023-08-08 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| CN114213509B (zh) * | 2022-02-22 | 2022-06-10 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗及其用途 |
| CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
| KR102850225B1 (ko) * | 2022-04-07 | 2025-09-18 | 엠큐렉스 주식회사 | 사스-코로나바이러스 2 감염증에 대한 rna 백신 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4604995A1 (en) | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN115960923A (zh) * | 2022-11-24 | 2023-04-14 | 威瑞生物科技(昆明)有限责任公司 | 一种包含非人种属调控元件的SARS-COV-2刺突蛋白mRNA及其构建方法与应用 |
| WO2024141784A2 (en) * | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Broadly protective betacoronavirus vaccines and compositions |
| CN120435314A (zh) * | 2022-12-29 | 2025-08-05 | 波普瓦克斯私人有限公司 | 多靶疫苗和治疗剂 |
| IL322194A (en) * | 2023-01-20 | 2025-09-01 | Astrazeneca Ab | Nucleic acid molecules |
| CN117003835A (zh) * | 2023-03-17 | 2023-11-07 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗 |
| WO2025027492A1 (en) * | 2023-07-31 | 2025-02-06 | Pfizer Inc. | Coronavirus antigen variants |
| GB202416789D0 (en) * | 2023-11-15 | 2025-01-01 | BioNTech SE | SARS-COV-2 immunogenic compositions |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2026047603A1 (en) * | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8278063B2 (en) | 2007-06-29 | 2012-10-02 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| BR112012002291A2 (pt) | 2009-07-31 | 2016-11-29 | Ethris Gmbh | "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos" |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| DK2970456T3 (da) | 2013-03-14 | 2021-07-05 | Translate Bio Inc | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| BR112016021345A8 (pt) * | 2014-03-17 | 2022-07-05 | Tapimmune Inc | Composições de vacina de molécula de ácido nucleico e usos das mesmas |
| SG10201912038TA (en) * | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2016138160A1 (en) * | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| EP4286012A3 (en) * | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| TW201729835A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018081638A1 (en) * | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| EP3558356A2 (en) * | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| WO2018151816A1 (en) * | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| EP3681514A4 (en) * | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CA3170575A1 (en) * | 2020-03-06 | 2021-09-10 | Michael Gordon Joyce | Vaccines against sars-cov-2 and other coronaviruses |
-
2021
- 2021-02-06 JP JP2022548194A patent/JP7438604B2/ja active Active
- 2021-02-06 EP EP21709270.9A patent/EP4100052A2/en active Pending
- 2021-02-06 CN CN202180013506.4A patent/CN115551545A/zh active Pending
- 2021-02-06 BR BR112022015565A patent/BR112022015565A2/pt not_active Application Discontinuation
- 2021-02-06 KR KR1020227028371A patent/KR20220140528A/ko not_active Withdrawn
- 2021-02-06 CA CA3170150A patent/CA3170150A1/en active Pending
- 2021-02-06 AU AU2021215938A patent/AU2021215938A1/en not_active Abandoned
- 2021-02-06 US US17/797,784 patent/US20230346914A1/en active Pending
- 2021-02-06 IL IL295377A patent/IL295377A/en unknown
- 2021-02-06 MX MX2022009707A patent/MX2022009707A/es unknown
- 2021-02-06 WO PCT/US2021/016979 patent/WO2021159040A2/en not_active Ceased
-
2023
- 2023-08-16 JP JP2023132619A patent/JP7443608B2/ja active Active
-
2024
- 2024-02-20 JP JP2024023916A patent/JP7832243B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021159040A5 (https=) | ||
| JP2024050973A5 (https=) | ||
| JP2023075344A5 (https=) | ||
| JP2023164537A5 (https=) | ||
| RU2447060C2 (ru) | Ингибиторы сфингозинкиназы | |
| RU2221795C2 (ru) | Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения | |
| US7932272B2 (en) | Antifungal agent containing heterocyclic compound | |
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| JP2019513770A5 (https=) | ||
| JP2011524422A5 (https=) | ||
| JP2003519068A5 (https=) | ||
| JPWO2021155243A5 (https=) | ||
| JP2002539128A5 (https=) | ||
| JP2005247867A5 (https=) | ||
| JPWO2020061284A5 (https=) | ||
| JP2007516205A5 (https=) | ||
| JP2011518816A5 (https=) | ||
| RU2015102333A (ru) | Жидкие препараты аминов и органических кислот, стабилизированные солями | |
| US20090227799A1 (en) | Novel Antimalarial Agent Containing Heterocyclic Compound | |
| JP2016507502A5 (https=) | ||
| JP2014501284A5 (https=) | ||
| RU2016117052A (ru) | Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства | |
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| JP2011522774A (ja) | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物 | |
| JP2020535154A5 (https=) |